porcin
circoviru
type
type
two
genotyp
porcin
circoviru
presum
widespread
swine
popul
current
specif
treatment
infect
rna
interfer
rnai
sequencespecif
rna
degrad
mechan
mediat
small
interf
rna
sirna
repres
possibl
therapeut
applic
treatment
viral
infect
studi
three
sirna
express
plasmid
psrepa
psrepb
psrepc
gener
target
three
differ
code
region
rep
protein
rep
pcv
sirna
use
inhibit
pcv
product
porcin
kidney
cell
line
cell
result
reveal
rep
gene
express
inhibit
psrepa
psrepb
psrepc
differ
degre
moreov
studi
also
show
product
reduc
sirna
psrepc
target
middl
region
rep
gene
prove
effici
sirna
inhibit
rep
express
viral
product
taken
togeth
data
suggest
rnai
could
investig
potenti
treatment
pcv
infect
porcin
circoviru
pcv
member
circovirida
famili
small
nonenvelop
spheric
singlestrand
dna
viru
two
type
pcv
name
presum
widespread
swine
popul
though
consid
nonpathogen
allan
et
al
infect
human
leukocyt
vitro
consid
potenti
risk
viral
transmiss
porcin
tissu
organ
use
xenotransplant
arteagatroncoso
et
al
associ
wwwelseviercomlocatevetm
veterinari
microbiolog
postwean
multisystem
wast
syndrom
pmw
clark
hard
clark
porcin
dermat
nephropathi
syndrom
pdn
rosel
et
al
furthermor
may
damag
immun
system
induc
immunosuppress
result
pathogeny
coinfect
segal
et
al
although
vaccin
develop
recent
effici
still
need
test
field
trial
thu
new
method
develop
control
infect
urgent
necessari
rna
pcv
synthes
product
infect
porcin
kidney
cell
recent
character
replic
speci
rna
synthes
includ
capsid
protein
rna
cr
eight
repassoci
rna
rep
rep
three
nsassoci
rna
five
repassoci
rna
rep
rep
three
nsassoci
rna
synthes
replic
cell
cheung
two
protein
deriv
fulllength
rep
splice
rep
essenti
pcv
dna
replic
mankertz
hillenbrand
report
mutat
rep
truncat
rep
protein
caus
reduct
viral
protein
synthesi
complet
shut
viral
dna
replic
cheung
therefor
suggest
rep
rep
could
target
inhibit
pcv
replic
rna
interfer
rnai
first
discov
plant
biologist
late
howev
molecular
mechan
remain
unclear
eleg
work
nematod
caenorhabd
elegan
show
rnai
evolutionarili
conserv
genesilenc
mechan
fire
et
al
posttransl
silenc
gene
express
occur
respons
introduct
homolog
doublestrand
rna
dsrna
cell
phenomenon
result
highli
specif
suppress
gene
express
past
year
rnai
becom
wide
use
experiment
tool
analyz
function
gene
repres
new
feasibl
approach
develop
effect
antivir
treatment
rnai
antivir
therapi
shown
inhibit
replic
human
immunodefici
viru
capodici
et
al
sever
acut
respiratori
syndrom
viru
wang
et
al
influenza
viru
ge
et
al
footandmouth
diseas
viru
therefor
rnai
would
accord
ingli
serv
new
strategi
battl
viral
infect
studi
three
sirna
specif
target
rep
gene
rna
design
use
inhibit
product
virus
result
suggest
rnai
technolog
might
serv
potenti
molecular
strategi
pcv
therapi
three
target
sequenc
nt
nt
code
region
rep
gene
select
serv
basi
design
two
complementari
sirna
templat
oligonucleotid
fig
synthes
anneal
insert
bamhi
hindiii
site
sirna
express
vector
cmv
neo
ambion
result
recombin
plasmid
design
psrepa
psrepb
psrepc
neo
neg
control
ambion
neg
control
plasmid
psneg
encod
hairpin
sirna
whose
sequenc
found
mous
human
pcv
genom
databas
rep
gene
rep
gene
amplifi
subclon
vector
pcdegfp
respect
fuse
n
terminu
enhanc
green
fluoresc
protein
egfp
control
immedi
earli
promot
human
cytomegaloviru
eukaryot
express
vector
name
fig
pcvfree
cell
cultur
dulbecco
modifi
eagl
medium
dmem
supplement
heatinactiv
foetal
bovin
serum
fb
shijiq
china
co
cell
plate
onto
plate
cultur
overnight
cell
reach
confluenc
transfect
separ
mg
psrepa
psrepb
psrepc
psneg
combin
mg
use
lipofectaminetm
invitrogen
accord
manufactur
recommend
nontransfect
cell
use
neg
control
fortyeight
hour
transfect
egfp
express
transfect
cell
examin
olympu
fluoresc
microscop
olympu
japan
egfp
posit
cell
egfp
express
signal
evalu
flow
cytometri
use
facscalibur
flow
cytometri
system
bd
usa
yu
strain
origin
isol
lymph
node
tissu
sampl
pig
natur
occur
pmw
cao
et
al
isol
cell
line
use
studi
tcid
pcv
determin
ifa
previous
describ
fenaux
et
al
twentyfour
hour
transfect
sirna
express
plasmid
cell
challeng
tcid
per
ml
h
adsorpt
inoculum
remov
cell
wash
twice
dmem
infect
perform
dmem
supplement
fb
seventi
two
hour
viral
challeng
viru
titer
detect
ifa
hand
rep
mrna
level
cell
h
postviru
challeng
protein
level
capsid
protein
cap
cell
h
postviru
challeng
evalu
realtim
rtpcr
western
blot
respect
standard
deviat
mean
student
ttest
determin
use
microsoft
excel
experi
experi
repeat
least
three
time
first
examin
egfp
express
cotransfect
cell
use
olympu
fluoresc
microscop
olympu
japan
compar
neg
control
cell
cotransfect
psneg
green
fluoresc
signal
reduc
cell
cotransfect
psrepa
psrepb
psrepc
respect
egfp
signal
detect
control
cell
fig
furthermor
inhibitori
effect
sirna
express
egfp
quantit
valid
flow
cytometri
analysi
h
transfect
extent
egfp
regul
quantit
assess
mean
fluoresc
posit
cell
percentag
egfp
posit
cell
shown
fig
c
mean
intens
egfp
signal
cell
transfect
psrepc
decreas
p
fig
percentag
egfp
posit
cell
reduc
compar
neg
control
p
fig
mean
intens
egfp
signal
cell
transfect
psrepc
decreas
p
fig
percentag
egfp
posit
cell
reduc
compar
neg
control
p
fig
psrepa
psrepb
result
weak
reduct
mean
intens
egfp
signal
p
percentag
egfp
posit
cell
p
studi
effect
sirna
viral
transcript
mrna
level
infect
cell
result
show
product
inhibit
significantli
psrepc
p
detect
realtim
rtpcr
fig
result
show
mrna
level
reduc
significantli
cell
transfect
psrepc
p
slight
decreas
found
cell
transfect
psrepa
psrepb
p
interestingli
express
cap
protein
pcv
also
inhibit
transfect
sampl
fig
psrepc
effici
sirna
plasmid
inhibit
cap
express
suggest
inhibitori
effect
occur
transcript
posttranscript
level
seventytwo
hour
postviru
infect
viru
titer
sirna
transfect
cell
control
cell
evalu
ifa
infect
mean
viru
tcid
cell
transfect
psneg
psrepa
psrepb
psrepc
respect
cell
without
transfect
tcid
fig
infect
mean
viru
tcid
cell
transfect
psneg
psrepa
psrepb
psrepc
respect
cell
without
transfect
tcid
fig
viral
titer
cell
lysat
transfect
psrepc
reduc
approxim
compar
control
group
p
howev
viral
titer
cell
transfect
psrepa
psrepb
reduc
p
respect
relat
pmw
diseas
consid
potenti
risk
viral
transmiss
porcin
tissu
organ
use
xenotransplant
arteagatroncoso
et
al
necessari
find
effici
method
pcv
treatment
studi
use
eukaryot
express
vector
report
system
monitor
function
sirna
express
evalu
fluoresc
microscopi
flow
cytometri
result
reveal
psrepa
psrepb
psrepc
specif
inhibit
rep
express
pcv
product
cell
furthermor
found
sirna
inhibit
rep
express
also
decreas
cap
protein
express
pcv
infect
cell
result
agreement
recent
studi
found
shrna
could
significantli
reduc
correspond
mrna
level
inhibit
viral
gene
transcript
well
j
therefor
assum
sirna
initi
degrad
rep
mrna
result
blockag
pcv
replic
protein
synthesi
accord
data
psrepc
target
middl
site
rep
gene
rna
appear
much
effici
psrepa
psrepb
target
end
end
rep
gene
rna
respect
indic
best
target
site
seem
close
midpoint
gene
recent
sirna
target
infect
cell
mous
model
report
author
demonstr
sirna
target
rep
gene
nt
effect
j
previou
studi
also
found
two
sirna
target
middl
sequenc
effici
inhibit
japanes
enceph
viru
replic
cell
x
phenomenon
may
due
differ
posit
access
caus
steric
hindranc
secondari
tertiari
structur
andor
protein
bind
yuan
et
al
addit
analysi
shown
nucleotid
predict
protein
homolog
suggest
sirna
target
sequenc
may
effici
studi
firstli
report
three
sirna
target
sequenc
inhibit
rep
express
viral
product
taken
togeth
research
demonstr
psrepa
psrepb
psrepc
effect
inhibit
pcv
rep
transcript
express
also
inhibit
pcv
product
cell
psrepc
effici
